Objective To investigate the efficacy of the combination of gemeitabine with eapeeitabine in the ehemotherapy for patients with relapsed or metastafie biliary tract eareinoma. Methods Forty-one patients with unreseetable relapsed or metastatic carcinoma of the biliary tract were treated from March 2000 to Deeember 2004. The regimen eonsisted of intravenous administration of gemeitabine plus oral intake of eapeeitabine every 3 weeks for more than 2 eyeles. The parameters ineluding tumor response,elinieal benefit rate,survival and safety were observed. Results Thirty-six patients were valuable and 5 patients were exeluded from this series due to various reasons. Eleven patients （30.1%） had a partial response and another 11 patients （30. 1% ） experieeed stable disease with a elinieal benefit rates of 61.1%. The median overall survival time and time to progression were 10 months and 6 months, respeetively. The one-year survival rate was 40.0%. The adverse events ineluding nausea, diarrhea and hand-foot syndrome, fatigue, neutropenia,thromboeytopenia were frequently observed, whieh were usually in grade Ⅰ or Ⅱ , rarely in grade Ⅲ and none in grade Ⅳ （NCI-CTC）. Conclusion Our results show that the regimen of gemeitabine combined with eapecitabine is effective and well tolerated in patients with unreseetable relapsed or metastatic carcinoma of the biliary tract.